Gene study reveals clues about ulcerative colitis risk and drug effectiveness
NCT ID NCT07564895
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study examined how differences in the BAFF gene might affect a person's risk of developing ulcerative colitis and how well they respond to the drug vedolizumab. Researchers analyzed genetic samples from 841 people with ulcerative colitis. The goal was to better understand the disease and potentially improve treatment choices in the future.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
the Second Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, 325000, China